Table 1. Observed and predicted 5-, 8-, and 10-year all-cause mortality by demographical, tumour ,and treatment characteristics.

	5 Years					8 Years					10 Years
Characteristic	N	O	P	D	%	N	O	P	D	%	N	O	P	D	%
Total	2827	607	455	−152	−25	1843	454	430	−24	−5.3	597	152	164	12	7.9
Age at diagnosis (years)
18–25	40	7	5	−2	−28.6	21	4	4	0	0	8	1	1	0	0
26–30	258	62	46	−16	−25.8	167	48	43	−5	−10.4	55	15	16	1	6.7
31–35	864	210	152	−58	−27.6	580	168	146	−22	−13.1	203	60	57	−3	−5
36–40	1665	328	252	−76	−23.2	1075	234	237	3	1.3	331	76	90	14	18.4
Menopausal status
Premenopause	2771	591	444	−147	−24.9	1801	440	420	−20	−4.5	581	148	162	14	9.5
Post-menopause	7	2	1	−1	−50	4	2	1	−1	−50	1	1	0	−1	−100
Perimenopause	5	2	1	−1	−50	5	2	2	0	0	3	1	1	0	0
Unknown	44	12	9	−3	−25	33	10	8	−2	−20	12	2	2	0	0
Morphology
Ductal	2447	531	410	−121	−22.8	1606	396	388	−8	−2	520	132	149	17	12.9
Lobular	129	27	10	−17	−63	79	21	12	−9	−42.9	30	8	4	−4	−50
Other	216	42	31	−11	−26.2	133	32	27	−5	−15.6	40	12	10	−2	−16.7
Unknown	35	7	4	−3	−42.9	25	5	4	−1	−20	7	0	1	1	.
Grade
1	156	5	4	−1	−20	98	5	4	−1	−20	31	3	2	−1	−33
2	929	161	67	−94	−58.4	614	121	75	−46	−38	200	44	31	−13	−30
3	1676	429	378	−51	−11.9	1097	322	346	24	7.5	351	103	129	26	25.2
Not graded/missing	66	12	7	−5	−41.7	34	6	5	−1	−16.7	15	2	2	0	0
LV invasion
Negative	1374	182	156	−26	−14.3	873	142	144	2	1.4	290	47	59	12	25.5
Positive	1253	385	272	−113	−29.4	845	287	264	−23	−8	270	96	99	3	3.1
Unknown	200	40	27	−13	−32.5	125	25	22	−3	−12	37	9	7	−2	−22
Node status
Negative	1370	161	128	−33	−20.5	869	111	115	4	3.6	266	39	42	3	7.7
Positive	1431	439	324	−115	−26.2	959	339	312	−27	−8	327	112	121	9	8
Unknown	26	7	4	−3	−42.9	15	4	3	−1	−25	4	1	1	0	0
Tumour size
0–10	265	42	20	−22	−52.4	161	29	17	−12	−41.4	48	14	7	−7	−50
11–20	930	125	100	−25	−20	629	99	99	0	0	221	41	45	4	9.8
21–50	1229	302	233	−69	−22.8	798	228	219	−9	−3.9	244	78	79	1	1.3
50+	244	99	85	−14	−14.1	171	75	83	8	10.7	54	13	28	15	115.4
Unknown	159	39	16	−23	−59	84	23	12	−11	−47.8	30	6	5	−1	−16.7
ER status
Negative	965	245	297	52	21.2	642	183	242	59	32.2	231	64	94	30	46.9
Positive	1862	362	158	−204	−56.4	1201	271	188	−83	−30.6	366	88	70	−18	−20.5
Local Rx
BCS+RT	1310	188	168	−20	−10.6	872	146	159	13	8.9	275	59	59	0	0
Mast+RT	1001	313	228	−85	−27.2	648	231	213	−18	−7.8	208	70	85	15	21.4
Mast alone	445	87	48	−39	−44.8	277	65	47	−18	−27.7	101	22	18	−4	−18.2
Other	71	19	12	−7	−36.8	46	12	10	−2	−16.7	13	1	3	2	200
Systemic Rx
None	46	4	5	1	25	28	3	5	2	66.7	6	1	1	0	0
Hormone	227	16	6	−10	−62.5	157	15	8	−7	−46.7	50	6	3	−3	−50
Chemo	986	261	297	36	13.8	659	198	248	50	25.3	237	71	94	23	32.4
Both	1568	326	147	−179	−54.9	999	238	170	−68	−28.6	304	74	66	−8	−10.8
HER2 status
Negative	1773	383	255	−128	−33.4	1059	273	234	−39	−14.3	327	82	83	1	1.2
Positive	679	183	159	−24	−13.1	434	141	141	0	0	140	50	53	3	6
Borderline	40	10	6	−4	−40	33	10	7	−3	−30	14	5	4	−1	−20
Unknown	335	31	35	4	12.9	317	30	49	19	63.3	116	15	24	9	60
Ethnicity
Caucasian/White	2582	547	413	−134	−24.5	1692	411	392	−19	−4.6	557	144	156	12	8.3
Black	110	36	21	−15	−41.7	74	27	20	−7	−25.9	17	5	4	−1	−20
Asian	84	15	14	−1	−6.7	55	11	13	2	18.2	16	3	3	0	0
Other	19	3	3	0	0	12	3	3	0	0	3	0	0	0	.
Unknown	32	6	5	−1	−16.7	10	2	2	0	0	4	0	1	1	.

Abbreviations: BCS=breast-conserving surgery; D=difference; ER=oestrogen receptor status; HER2=human epidermal growth factor receptor 2; LV=lymphovascular invasion; N=number of patients; O=number of observed events; P=number of predicted events; RT=radiotherapy; Rx=Treatment.